Track Cytokinetics, Incorporated — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cytokinetics, Incorporated CYTK · Stock Open Cytokinetics, Incorporated in new tab

56.13 USD
EPS
-6.02
P/B
-24.33
Beta
0.47
Target Price
109.42 USD
Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

🧾 Earnings Recap – Q1 2026

Cytokinetics’ Q1 results were buoyed by the strong commercial launch of MYQORZO in the U.S., with initial revenue and prescriber engagement exceeding internal expectations, driving a 13.3% stock gain.

  • MYQORZO generated $4.8 million in net product revenue in its first partial commercial quarter.
  • Over 90% of high-volume cardiomyopathy (CMI) prescribing physicians were detailed by the sales force in Q1.
  • More than 40% of MYQORZO prescriptions came from lower-volume or first-time CMI prescribers, indicating early breadth in adoption.
  • Positive topline Phase III results from ACACIA-HCM showed aficamten improved symptoms and exercise capacity in nonobstructive HCM with no new safety concerns.
  • Regulatory progress includes FDA acceptance of the MAPLE-HCM supplemental NDA with a PDUFA date set for November 14, 2026, and filings or approvals advancing in Europe, Switzerland, Canada, Hong Kong, and Taiwan.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
EPS-6.02
Book Value-2.31
Price to Book-24.33
% Insiders1.198%
Growth
Revenue Growth23.57%
Estimates
Forward P/E-13.26
Forward EPS-4.23
Target Mean Price109.42

DCF valuation

Model fair value for Cytokinetics, Incorporated (CYTK)
Result
Sign in to run the valuation for CYTK.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
19 analysts · consensus Strong buy · mean target 109.42 USD (low 78.00, high 146.00) · as of 15 Nov 2026
Low 78.00
Mean 109.42
High 146.00
Price 56.13
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cytokinetics, Incorporated Logo Cytokinetics, Incorporated Analysis (CYTK)

United States Health Care Official Website Stock

Is Cytokinetics, Incorporated a good investment? Cytokinetics, Incorporated (CYTK) is currently trading at 56.13 USD. Market analysts have a consensus price target of 109.42 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cytokinetics, Incorporated is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is -4.23.

Investor FAQ

Does Cytokinetics, Incorporated pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cytokinetics, Incorporated?

Cytokinetics, Incorporated is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -6.02.

Company Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) CYTK
FRA (Germany) KK3A.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 25, 2013 1:6
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion